BioWorld® - Medical Device Daily
BioWorld® - Medical Device Daily
BioWorld® - Medical Device Daily
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information<br />
Genzyme Corp.<br />
500 Kendall Street<br />
Cambridge MA 02142, US<br />
Phone: (617) 252-7500; Fax: (617) 252-7600<br />
Web: www.genzyme.com; E-mail: info@genzyme.com<br />
KEY PERSONNEL: Henri A. Termeer; Chairman, President and CEO<br />
Mara G. Aspinall; President, Genetics<br />
Mark R. Bamforth; Sr. VP, Corporate Operations and Pharmaceuticals<br />
John Butler; President, Genzyme Renal<br />
Earl M. Collier Jr.; Exec. VP, Cardiovascular and Oncology<br />
Thomas J. DesRosier; Sr. VP, General Counsel and Chief Patent Counsel<br />
Richard H. Douglas, Ph.D.; Sr. VP, Corporate Development<br />
David D. Fleming; Group Sr. VP<br />
Georges Gemayel; Exec. VP, Therapeutics, Transplant and Renal<br />
James A. Geraghty; Sr. VP<br />
Elliott D. Hillback Jr.; Sr. VP, Corporate Affairs<br />
Alison Lawton; Sr. VP, Regulatory Affairs and Corporate Quality Systems<br />
Evan M. Lebson; VP and Treasurer<br />
Roger W. Louis; VP, Healthcare and Regulatory Counsel and Chief<br />
Compliance Officer<br />
Mary McGrane; VP, Government Relations<br />
John M. McPherson, Ph.D.; Sr. VP, Cell and Protein R&D<br />
David Meeker, M.D.; President, Lysosomal Storage Disorder Therapeutics<br />
Ann Merrifield; President, Genzyme Biosurgery<br />
Richard A. Moscicki, M.D.; Sr. VP, <strong>Medical</strong>, Clinical and Regulatory Affairs<br />
and CMO<br />
Donald E. Pogorzelski; President, Genzyme Diagnostics<br />
Alan E. Smith, Ph.D.; Sr. VP, Research and CSO<br />
Sandford D. Smith; President, International Group<br />
Peter T. Traynor; VP and Corporate Controller<br />
Peter Wirth; Exec. VP, Legal, Corporate Development and Drug Discovery,<br />
Chief Legal Officer and Secretary<br />
Michael S. Wyzga; Exec. VP, Finance, CFO and CAO<br />
EMPLOYEES: 8,500+ employees<br />
HISTORY: Founded in June 1981 by Henry Blair and Sherry Snyder<br />
Began operations by acquiring Whatman Biochemicals Ltd., U.K.<br />
Member--Biotechnology Industry Organization<br />
Founded 16 labs (1990)<br />
Formed Neozyme Corp. to fund development of programs (10/90)<br />
Formed Neozyme II to fund the research, development, and clinical testing<br />
of biotherapeutic products for the treatment of cystic fibrosis (4/92)<br />
Subsidiary IG Laboratories Inc. purchased Genetic Design Inc., a privately<br />
held genetic testing company (6/92)<br />
Acquired phospholipid business of Enzymatix Ltd. (6/92)<br />
Acquired Medix Biotech Inc. (6/92)<br />
Acquired Vivigen Inc., in exchange for stock valued at $40M (11/92)<br />
Neozyme I buyback of four programs, $49M (12/92)<br />
Established Genzyme Transgenics (now GTC Biotherapeutics) for<br />
producing human biotherapeutic products in the milk of transgenic animals<br />
(2/93)<br />
Acquired diagnostic business Virotech System-Diagnostika GmbH (4/93)<br />
Acquired diagnostic business Omnia Res srl (5/93)<br />
Neozyme I buyback of two programs, $49M (12/93)<br />
Acquired Swiss pharmaceutical manufacturer, Sygena Ltd. (7/94)<br />
Subsidiary Genzyme Transgenics purchased TSI, a publicly held clinical<br />
testing and production company (10/94)<br />
Created Genzyme Tissue Repair by acquiring BioSurface Technology Inc.<br />
and combining with several of Genzyme Corp.'s tissue repair programs<br />
(12/94)<br />
Acquired all shares of IG Laboratories Inc. (9/95)<br />
Copyright ©2006 AHC Media ® 174
Change language